跳至主要内容
临床试验/DRKS00000722
DRKS00000722已完成不适用

oninterventional Study of Safety, Efficacy, Adherence, and Health Related Quality of Life in Patients Receiving a Once Daily Single Tablet Regimen for HIV 1 Infection in GermanySTR-NIS – (STRike) - STRike

Gilead Sciences GmbH0 个研究点目标入组 874 人开始时间: 2011年2月25日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
874

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • Arm 1 and 2: Adults with HIV-1-infection, who are with their current antiretroviral combination therapy virologically suppressed (HIV-1-RNA < 50 copies/ml) for at least three months.
  • Arm 3: Antiretroviral naive adults with HIV-1-infection and viral load of <= 100.000 copies HIV-1-RNA/ml
  • arm 4 - Adults with HIV-1 infection, who are antroretroviral treatment-naïve or are infected with HIV-1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild

排除标准

  • Patients not fulfilling the inclusion criteria.

研究者

相似试验